Physiomics to present cardiac toxicity platform

RNS Number : 0096O

Physiomics PLC

13 September 2013

 



Physiomics plc

The Magdalen Centre

The Oxford Science Park

Robert Robinson Avenue

Oxford

OX4 4GA

UK

Tel [phone]

Fax [phone]

16 September 2013                   

Physiomics plc

("Physiomics") or ("the Company")

Physiomics to present on the cardiac toxicity platform at the 2013 Safety Pharmacology Society's Annual Meeting ("SPS")

Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is participating in the 2013 Safety Pharmacology Society's  annual Meeting (SPS), taking place at the Congress Centre de Doelen, Rotterdam, Netherlands, on 16-19 September 2013. Dr Hitesh Mistry will present the latest modelling advances of the cardiac toxicity predictive platform developed at Physiomics.

The platform uses readily available lab-based data to predict the risk that drugs in development will have serious cardiac side effects which could lead to drug program closure.  Three versions of the model are now available, two to predict outcomes in animal experiments, dog and rabbit, and a third one to predict cardiac liability in humans.  Benchmarking tests against state of the art models will be presented in the poster. The results show that the Physiomics model is more predictive than the state of the art models. Furthermore, given that the same structural model is used for making predictions in different species, the model is ideally placed to make translational predictions, i.e. from animal to human.

The abstract #23 ("Predicting Cardiac Toxicity from Data Generated via High‐Throughput Screening") will be presented in the "Disease Models, In Silico, Exploratory Pharmacology" session.

More information about the conference may be found at:

http://www.safetypharmacology.org/am2013/

Dr Mark Chadwick, CEO of Physiomics, commented:

"We are delighted to present the progress of our cardio tox platform at the SPS meeting as part of our roll out of this new service, which has already attracted significant interest from our large pharma partners."

Enquiries:

Physiomics plc                                                  

Dr Mark Chadwick, CEO

[phone]

WH Ireland Limited (broker/nomad)

Katy Mitchell

[phone]

About Physiomics plc

Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million¹.

Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.

Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com

SystemCell® is a registered trademark of Physiomics plc

¹Tufts Centre Impact Report 2002

 

END

 

 

NRAUOVVRONAKAAR